Scholarlink

Background <p>Bone metastasis in lung cancer worsens prognosis, highlighting the need for reliable serum biomarkers for early detection and risk stratification.</p> Methods <p>Five databases were searched. Study selection, data extraction, and quality assessment were performed. Meta-analyses were conducted to assess the association between biomarkers and bone metastasis. Heterogeneity was assessed using Cochran’s Q and I<sup>2</sup> tests. Subgroup analyses, meta-regression, and sensitivity analyses were performed, and publication bias was evaluated using funnel plots, Egger’s test, and the trim-and-fill analysis.</p> Results <p>A total of 119 studies involving 12,409 patients were included. Pooled analyses showed significant associations between bone metastasis and several biomarkers, including traditional tumor markers: CEA (SMD = 3.03, 95% CI 2.52–3.55, P &lt; 0.001), CA125 (SMD = 3.82, 95% CI 3.04–4.60, P &lt; 0.001), CA153 (SMD = 2.52, 95% CI 0.98–4.06, p = 0.001), and CYFRA21-1 (SMD = 1.68, 95% CI 1.37–1.99, P &lt; 0.001); bone formation markers: bALP (SMD = 2.84, 95% CI 1.78–3.90, P &lt; 0.001), T-ALP (SMD = 1.28, 95% CI 0.43–2.13, p = 0.003), PINP (SMD = 1.59, 95% CI 1.10–2.07, P &lt; 0.001), and N-MID (SMD = 0.86, 95% CI 0.37–1.36, p = 0.001); bone resorption markers: β-CTX (SMD = 1.35, 95% CI 0.82–1.88, P &lt; 0.001), NTx (SMD = 1.74, 95% CI 1.07–2.41, P &lt; 0.001), and ICTP (SMD = 2.11, 95% CI 1.50–2.72, P &lt; 0.001); and bone microenvironment and regulatory factors: BSP (SMD = 1.62, 95% CI 1.21–2.02, P &lt; 0.001), ODF (SMD = 4.59, 95% CI 3.92–5.25, P &lt; 0.001), calcium (SMD = 1.18, 95% CI 0.77–1.60, P &lt; 0.001), OCIF (SMD = 4.97, 95% CI 3.64–6.30, P &lt; 0.001), PTHrP (SMD = 0.88, 95% CI 0.68–1.08, P &lt; 0.001), calcitonin (SMD = 1.81, 95% CI 0.48–3.15, p = 0.008), and calcineurin (SMD = 3.51, 95% CI 2.31–4.71, P &lt; 0.001). In contrast, NSE, CICP, osteocalcin, CTX, TRACP-5b, and RANKL/OPG were not consistently associated. Subgroup and sensitivity analyses confirmed the robustness of most findings, though heterogeneity and publication bias were noted.</p> Conclusions <p>Multiple serum biomarkers are associated with lung cancer bone metastasis and may serve as complementary tools for early detection and risk stratification.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative evaluation of four categories of serum biomarkers for detecting bone metastasis in lung cancer: a systematic review and meta-analysis of 119 studies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月21日

查看全文
  • Caiyang Liu,
  • Xing He,
  • Yu Lei,
  • Hong Shao,
  • Lei Luo,
  • Yi Wang,
  • Ji Li,
  • Ran Ran

摘要

Background

Bone metastasis in lung cancer worsens prognosis, highlighting the need for reliable serum biomarkers for early detection and risk stratification.

Methods

Five databases were searched. Study selection, data extraction, and quality assessment were performed. Meta-analyses were conducted to assess the association between biomarkers and bone metastasis. Heterogeneity was assessed using Cochran’s Q and I2 tests. Subgroup analyses, meta-regression, and sensitivity analyses were performed, and publication bias was evaluated using funnel plots, Egger’s test, and the trim-and-fill analysis.

Results

A total of 119 studies involving 12,409 patients were included. Pooled analyses showed significant associations between bone metastasis and several biomarkers, including traditional tumor markers: CEA (SMD = 3.03, 95% CI 2.52–3.55, P < 0.001), CA125 (SMD = 3.82, 95% CI 3.04–4.60, P < 0.001), CA153 (SMD = 2.52, 95% CI 0.98–4.06, p = 0.001), and CYFRA21-1 (SMD = 1.68, 95% CI 1.37–1.99, P < 0.001); bone formation markers: bALP (SMD = 2.84, 95% CI 1.78–3.90, P < 0.001), T-ALP (SMD = 1.28, 95% CI 0.43–2.13, p = 0.003), PINP (SMD = 1.59, 95% CI 1.10–2.07, P < 0.001), and N-MID (SMD = 0.86, 95% CI 0.37–1.36, p = 0.001); bone resorption markers: β-CTX (SMD = 1.35, 95% CI 0.82–1.88, P < 0.001), NTx (SMD = 1.74, 95% CI 1.07–2.41, P < 0.001), and ICTP (SMD = 2.11, 95% CI 1.50–2.72, P < 0.001); and bone microenvironment and regulatory factors: BSP (SMD = 1.62, 95% CI 1.21–2.02, P < 0.001), ODF (SMD = 4.59, 95% CI 3.92–5.25, P < 0.001), calcium (SMD = 1.18, 95% CI 0.77–1.60, P < 0.001), OCIF (SMD = 4.97, 95% CI 3.64–6.30, P < 0.001), PTHrP (SMD = 0.88, 95% CI 0.68–1.08, P < 0.001), calcitonin (SMD = 1.81, 95% CI 0.48–3.15, p = 0.008), and calcineurin (SMD = 3.51, 95% CI 2.31–4.71, P < 0.001). In contrast, NSE, CICP, osteocalcin, CTX, TRACP-5b, and RANKL/OPG were not consistently associated. Subgroup and sensitivity analyses confirmed the robustness of most findings, though heterogeneity and publication bias were noted.

Conclusions

Multiple serum biomarkers are associated with lung cancer bone metastasis and may serve as complementary tools for early detection and risk stratification.